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ABSTRACT 
 
Background: Pulmonary Tuberculosis (PTB) is considered a disease of the past but it remains a 
major cause of mortality among immune compromised patients and continues to be a significant 
threat to public health globally. Notably, the prevalence of diabetes mellitus (DM) has increased 
over the years. The biological link of TB and DM has been reported in numerous literature with 
DM attributed to three folds increase in the risk of TB and linked to Drug Resistant TB, especially 
amongst aged diabetic patients. The aim of the study was to examine the distribution of DM 
among TB patients and explore the risk of Drug resistant TB in Diabetics infected with TB 
 
Methods: The study employed a retrospective cross-sectional descriptive case based study 
involving 3638 patients diagnosed with pulmonary TB in the State of Florida, USA, 2009-2014. A 
comparative analysis of TB cases with DM and cases without DM adjusted for age was conducted. 
The risk of Drug resistant TB associated with DM was estimated through logistic regression 
analysis. Odds Ratios of TB/DM comorbidity were calculated and adjusted for Age using 5-year 
intervals from 40 years to above 70 years. Ninety-five percent (95%) confidence intervals were 
used and the accepted level of error was 0.05.  
 
 
Results: There were 3836 cases of Pulmonary TB in Florida for the period of 2009-2014. The 
majority of cases (65%) were males and likely unemployed (59.1%). The prevalence of DM was 
vi 
 
12 % but when adjusted for age the prevalence of DM was 3.9% amongst patients aged below 40 
years and 16.7 % in patients aged above 40 years. An estimated 469 cases had TB/DM 
comorbidity (12.2%). The majority of TB/DM cases were above 40 years amongst the patients 
with DM, 44/469 (9.4%) had drug resistant TB and a majority were resistant to Rifampin. 
Population density did not influence the distribution of TB in this study. 
 
Conclusion: Diabetes Mellitus, Aging, and low immunity are linked with increased rates of 
progressing from latent TB infection to active disease. To achieve the goal of TB elimination it is 
important to fully understand and identify known TB comorbidities for proper diagnosis and 
early initiation to care. There is a positive correlation between high DM burden and increased TB 
prevalence. Therefore, it is recommended that prevention of DM, hyperglycemia and 
comprehensive management of DM be intensified to prevent TB, improve TB treatment outcomes 
and reduce the risk of drug resistant TB in Florida, USA.
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1. CHAPTER ONE: INTRODUCTION 
1.1. Background  
Tuberculosis (TB) is a significant cause of mortality among immune compromised patients and 
continues to be a significant threat to humans globally[1]. The Center for Disease Control and 
prevention (CDC) defines TB as a bacterial infection caused by Mycobacterium Tuberculosis. TB 
has been recognized by the World Health Organization (WHO) as the most common cause of 
death among people with Human Immune Deficiency Virus (HIV), responsible for a reported 
25% mortality of global Acquired Immune Deficiency Syndrome (AIDS) death in 2013 [2]. 
Notably, the prevalence of Diabetes Mellitus (DM) has increased in countries with a high burden 
of TB [3]. The physiological link between the two epidemics has been recognized throughout 
history [4].  
 
Diabetes is a group of metabolic disorders marked by high blood glucose levels. It is entirely 
dependent on how insulin is produced, regulated or both. There are two types of DM, type 1, 
formerly known as insulin dependent diabetes mellitus and type 2 DM, formerly known as non-
insulin dependent DM (WHO). They both present with a similar range of complications, 
however, the significant difference is their time of onset or diagnosis [3]. This research focused 
on diabetes mellitus without disaggregating the type among patients with TB, exploring their 
characteristics as well as their risk of drug resistant TB. Type 2 DM accounts for 90-95% of all DM 
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diagnosed cases and the most observed in TB/DM comorbidity. It is associated with old age, 
obesity, lifestyle practices and race. Blacks and Hispanics are most at risk [3]  
 
1.2. Problem statement 
 
The United States reported 9421 cases of TB in 2014 [5]. According to CDC, the prevalence of TB 
as of 2014 was 9.6/100 000 persons. TB is considered a disease of the past but it is still a major 
cause of mortality in developing countries and Asia [5]. CDC and the WHO estimate that 2 billion 
people globally are infected with mycobacterium tuberculosis [5].  The United States saw a 
resurgence of the disease in 1985 due to multiple factors including increased prison population, 
homelessness, injection drug use, overcrowding of houses, and an increase of populations in long 
term care facilities. Immigration of people from endemic countries has been cited as a 
contributing factor to TB transmission. Further fueling factors are HIV and DM. TB kills 2-3 
million people annually worldwide and is the leading cause of death among young adults [1]. 
Most concerning is that 4% of TB cases are resistant to at least more than one anti-TB drug, 
however, drug resistant TB is rare in the United States [2].  Medical interventions, improved 
diagnostics and treatment have rendered TB curable but proper treatment and adherence to 
treatment is not easily attainable. The prevalence of TB among diabetics is high and has been 
since ancient history as documented by Root H in 1934 13 [6]. This article observed that TB is 
much more common amongst patients whose diabetes is poorly managed [6].  
 
In Philadelphia, Kelly E Dooley and Richard E Chaisson, cited a study where there was an 
observed two-fold increase in TB prevalence among diabetics. A dose-response pattern was also 
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observed in patients with diabetes who needed increased insulin units per day as they were 
double the risk of TB compared to patients who required lower doses [7]. A major limitation 
amongst the growing body of studies looking at the association between TB and Diabetes is the 
use of active TB cases in studies compared to latent TB infection which may either overestimate 
of underestimate the strength of association between TB and DM. The interactions between 
Diabetes and TB is most critical at analyzing TB/DM comorbidity. It is known that diabetes 
increases the severity of TB and negatively affects treatment outcomes amongst patients taking 
anti TB drugs [4]. Research highlights that diabetes lowers a patients’ immunity and subsequently 
results in increased incidents of relapse following treatment and prolonged culture conversion 
rates [8]. 
 
A study in Turkey observed longer sputum conversion rate of 67 days amongst people with 
diabetes compared to 55 days amongst patients without diabetes [9]. Diabetes further influences 
treatment success among TB patients. In Egypt, TB patients with diabetes were estimated at 3.9 
increased risk of treatment failure [10]. To support this observation, an Indonesian study 
observed that there was 22.2 % of positive sputum cultures among TB patients with diabetes as 
compared to 6.9 % in TB patients at 6 months’ sputum culture.  
 
Most significantly, a 41 % treatment failure in TB/DM comorbidity was observed compared to 
only 13 % of patients without Diabetes [7]. On a global scale, the risk of TB death amongst 
diabetics is estimated at 6.5-6.7 which is evident that the risk is a public health threat [11]. 
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Deaths and treatment failure are common in TB/DM comorbidity. Poorly managed diabetes 
increases susceptibility to TB. This is attributable, amongst other factors, to hyperglycemia which 
is a major diabetes complication that affects cellular immunity, in particular, the macrophages 
[12]. Macrophages are significant in mycobacterium TB containment and their ability to 
physiologically function is impaired by diabetes [3, 13].  
 
Despite the high prevalence of TB among people with diabetes, the pathological relationship 
remains understudied. Estimates show that 180 million people are suffering from DM and this is 
likely to double by 2030 [14]. The observed correlation between TB and diabetes could have a 
negative impact on TB control programs [15].  Patients with diabetes have a weak immunity and 
are prone to getting infections including TB which dents global TB control initiative [3]. 
 
1.3. Hypothesis 
Aging is associated with diminished immunity. Macrophages, which play a pivotal role in the 
first line defense of pathogen invasion, have their endocytosis and lysosomal action delayed as 
people age. The capacity, therefore of alveolar macrophages to kill Mycobacterium tuberculosis 
is significantly compromised in aging populations. DM tends to lower a persons’ immunity as 
evident in many studies [Nuria et al], hence, the hypothesis of this study was that the prevalence 
of DM is higher amongst TB patients and there is an increased risk of drug-resistant TB with age 
among diabetic patients.  
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1.4. Study goals and objectives 
The Primary goal of the study was to examine the distribution of DM among TB patients and 
explore the risk of Drug-resistant TB in Diabetics who are also infected with TB in Florida, USA. 
The Florida department of health TB control program aims to eliminate TB in the state through 
TB care initiative, A Florida system of Tuberculosis care formed by a partnership between the 
Florida Department of Health (FDOH) and the public health system statewide to ensure 
availability of effective TB management program, an aim in line with the global plan to stop TB 
2016-2020 adopted by WHO has a post 2015 strategy to eliminate TB as a global epidemic by 2035. 
The research aimed to gain in-depth understanding of TB and drug-resistant TB risk associated 
with DM in aging populations to initiate collaborative TB/DM control initiatives throughout the 
state of Florida as well as identify counties with the highest risk of disease through spatial analysis 
and in doing so, contribute to the body of evidence in the state and country available for decision 
making and planning. 
 
1.4.1   Main objective 
The Primary goal of the study was to examine the distribution of DM among TB patients and 
explore the risk of Drug-resistant TB in Diabetics in Florida, USA using secondary data sources 
from the Florida department of health, American diabetes association, Florida TB control 
program and the Center for Disease Control.  
 
1.4.2. Specific objectives 
a.    To describe the characteristics of TB patients co-infected with DM   
b.    To determine if Drug Resistant TB is associated with DM among Patients with Pulmonary  
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 TB. 
c.    To determine whether level of urbanization, using population density as a proxy, is positively 
 associated with increased rates of TB/DM Comorbidity in the state of Florida counties.  
 
1.5. Public health significance 
The double burden of TB and DM is a significant Public health threat, understandably so because 
of the increase in diabetic patients among countries where TB is endemic [3, 7]. Individually TB 
and DM each present a burden on any public health system, however, together they form a 
significant public health threat that warrants urgent interventions[3]. In the beginning of the 19th 
century one in seven Americans were killed by TB, however with the development of highly 
effective TB drugs in the 1940’s, there was a decline in TB cases [16]. With the emergence of the 
HIV epidemic in the 1980’s, there was a noticeable rise in TB cases in the US as with the rest of 
the world (CDC). HIV is not the only risk factor for TB disease, other causes of 
immunosuppression increase the risk for TB disease such as DM. DM is becoming an epidemic 
attributed to diet, sedentary lifestyles and genetics (WHO). In countries with TB epidemics and a 
rising DM prevalence, control of TB has become tenuous and unless collaborative control efforts 
are implemented, the world will continue to struggle with eliminating TB disease. The TB/DM 
dual burden has recently received attention due to the recent spike of TB amongst diabetics in the 
Middle East and has been classified as a dual burden due to the negative impact on the health 
systems in countries with an already high TB incidence [3].  
TB/DM comorbidity is a major public health problem because global efforts pioneered by WHO 
and CDC in controlling TB are undermined by the increased TB risk posed by DM. DM increases 
TB risk by three folds which is a major drawback to public health [17]. DM does not only increase 
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the risk of progressing from latent TB infection to active TB disease but makes TB disease more 
severe and negatively impacts on TB treatment outcomes with a risk of 1.89 for dying and a risk 
of 1.69 for treatment failure and dying combined [18]. Relapse following treatment is estimated 
at 3.89 amongst diabetics putting them at higher risk of developing Multi Drug Resistant TB 
(MDR-TB) which causes, increased costs of managing TB [18]. This makes TB control efforts 
harder and unless all possible control interventions are explored people will continue dying from 
the deadly but preventable and curable disease. Interesting findings from a recent study point 
out that by 2035 there will be an 8.8% cumulative increase in the incidence of TB by if the diabetes 
prevalence continues to increase at the current rate [19]. This study looked at TB transmission in 
13 countries and used epidemiological models to estimate the burden of TB that can be reduced 
through various DM prevention scenarios. According to their models, if the prevalence of 
diabetes could be lowered by 6.6-13.8 % TB incidence would decline by 11.5-25.2 (Absolute level) 
and subsequently mortality to TB would decline by 8.7 – 19.4 %. This translates to 6 million 
incident cases prevented and 1.1 million deaths to TB. Hence, by 2035, 7.8 million cases of TB 
would be prevented and 1.5 million deaths prevented. These projections present empirical data 
that if synergies between infectious and non-infectious disease control programs are established 
unwarranted deaths can be prevented and morbidity to TB controlled in the United States and 
globally [20].  
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2. CHAPTER TWO: LITERATURE REVIEW 
Data from the CDC show a decline in national TB cases in the United States since 1993 but TB 
control efforts have not resulted in the goal of elimination [21]. In 2014, WHO estimated that there 
were 9.6 million new cases of TB with a reported 1.5 million deaths globally [2] and in the United 
States alone, 9,412 cases of TB were reported in 2014, with an incidence rate of 3.0/100,000 
persons, a decrease of 2.2% from 2013 [5]. The total numbers of TB cases continue to decline, 
however, this is the smallest percentage decrease in over a decade [5] 
HIV has been for years the leading risk factor for mortality but the attributable proportion of HIV 
to TB mortality in 2014 was 0.4 million out of 1.5 million deaths [5, 22]. This is indicative of other 
key players increasing the risk of mortality besides HIV, such as diabetes. The biological and 
physiological links between TB and DM are not novel concepts since this association has been 
recognized from ancient history but with medical advancement, insulin introduction for DM 
coupled with Streptomycin discovery for TB substantially reduced cases of TB and DM [23].  
 
This study aimed to examine the distribution of DM among TB patients and explore the risk of 
Drug resistant TB in Diabetics who are also infected with TB in Florida, USA, using age as an 
effect modifier. Florida population has a median age of 41 years with the aging population 
representing 39.1 % of the population according to Florida population estimates. The American 
diabetes association, CDC and WHO have indicated that as people get older there is an increased 
risk of type 2 DM [3, 24]. This age group has a double risk of aging and immune suppression that 
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makes them hypothetically at an increased risk of opportunistic infections like TB particularly 
when they are diabetic [3]. 
 
Other literature have shown that the comorbidity of these diseases increases the severity of the 
other in infected persons [25]. There is a growing body of literature that supports the association 
between TB and DM [3], however, results have been inconsistent.  It is without a doubt that 
TB/DM comorbidity complicates TB control and treatment outcomes [23]. A population based 
study that was conducted in California observed that Diabetes accounts for a 3.5 times risk 
increase of TB as compared to persons without diabetes [21] 
 
The study further pointed out that the risk of TB caused by diabetes varies by age group with 
the old age posing a lower risk. These findings are an antagonist to other research particularly a 
meta- analysis study conducted in Mexico which observed that risk of TB increases with age 
amongst diabetics [26]. WHO suspects that the increased burden of Diabetes undermines global 
TB control efforts [2]. A temporal association has been suggested between increased TB 
incidence and rapid industrialization and urbanization which could be plausibly explained by 
the increased TB transmission associated with migration, population density, emergence of non-
communicable diseases like diabetes and overcrowding observed during the peak transmission 
in Great Britain between the 17th and 18th Century [27]. Rural or urban settlement has been 
implicated in various diseases and the prevalence of diabetes has been reported to be high in 
urban developments compared to rural[28].  
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Additionally, TB interacts with DM with a reported three times higher risk of progression to 
MDR-TB in these patients. Evidence further shows that TB and DM drugs counteract each other 
complicating the conditions even further[25]. A study was conducted in Egypt to study predictors 
of treatment failure among people undergoing TB treatment utilizing the DOTS strategy and it 
was observed that diabetes confers an estimated 3.9 times increased risk of treatment failure [29].  
TB infection and disease are biologically complicated. The disease progresses quickly from TB 
infection to acute TB infection in people with weakened immune system. In most instances, the 
body’s immune system initially fights off infection and contain the disease as latent TB infection 
[17]. 
 
An estimated one-third of the world’s population has latent TB infection [29]. About 90 % of 
diabetes cases are type 2 diabetes mellitus which explains why most of TB/DM comorbidity has 
a high proportion of people with Type 2 diabetes [30]. In Tanzania D. Faurholt-Jepsen et al 
reported that diabetes is strongly associated with increased mortality amongst TB patients 
especially after starting TB treatment [31]. His findings indicate DM as a stronger predictor of 
death since it negatively affects treatment outcomes. Multiple studies as indicated by D. Faurholt 
et al report more advanced pulmonary TB amongst patients with DM since DM is associated with 
delayed sputum conversion which further affects TB diagnosis and subsequently reduction in 
treatment success rate. An explanation for this phenomenon is the biologically plausible fact that 
DM affects the absorption and metabolism of TB drugs such as rifampicin. Diabetes is a known 
immune suppressor exposing patients with latent TB to fast progression to active TB.  
TB just like HIV weakens the immune system, though the immunological defects have not been 
characterized, the effect of diabetes on the immune system cannot be cast to doubt. In persons 
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without compromised immunity, the body initially fights off infection and contain the disease as 
latent TB infection, however, when the immune system gets compromised the body’s ability to 
fights off disease is limited. Alarmingly. A third of the world’s population has latent TB and is at 
an explosive risk of progressing to active TB if DM continues to be poorly managed [17]. 
 
Despite the observed association between TB and DM, the role of DM in TB risk has not been 
fully studied. The link between TB and DM has long been established yet diabetes continues to 
complicate TB control efforts [3]. DM is much likely to complicate the TB problem further as there 
is a global increase in DM cases. Like HIV, Diabetes weakens the immune system and permits 
progression of Latent TB infection to active TB. TB symptoms in TB/DM coinfection are 
convoluted complicating the identification and treatment resulting in lower case detection rates, 
misdiagnosis and poor treatment outcomes [32].  
 
There is evidence of interaction between Rifampicin and insulin which are the drugs of choice for 
TB and Diabetes which exert strain on TB case management [4], Rifampicin is also known to 
induce hyperglycemia which affects the control of diabetes. There is a global need to study and 
greater understand TB/DM comorbidity to effectively manage DM and prevent an increase in TB 
cases [33]. Further evidence highlights that TB might not only worsen glycaemic control but could 
also predispose patients to DM since Rifampicin which is the first line drug for TB causes 
hyperglycemia and has been associated with hyperinsulinemia not only in diabetic patients but 
non-diabetics as well [7]. 
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2.1.  Epidemiology of TB  
 
The incidence rate of TB in the United States was at 3.0 / 100000 people in 2014. The CDC 
highlighted this as a decline, however, this is the smallest decline in prevalence in a decade [5]. A 
strategic plan for TB control was developed by the CDC in 1989 and a goal to eliminate TB from 
the USA in 2015 was established and this initiative lead to a decline of TB cases from 1993 to 
current date. Statistics periodically indicate a substantive decline in TB cases but cases are still 
reported [5]. It is, therefore, important to understand state and county epidemiology of TB to 
monitor disease trends in the population. 
 
TB counts and prevalence rates have declined nationally among US-born people, however, the 
total number of cases have steadily increased among foreign born individuals. According to the 
CDC, foreign-born persons were 13.4 times more likely to have TB than US-born persons in 2014. 
During the same reporting year, 2014, minority groups, blacks, Asians and Hispanics continued 
to record the highest number of TB cases. Asians had the highest rate and were 28.5 times more 
likely to have TB than whites. Four states in the US (California, Florida, Texas and New York) 
housed about 50 % of the national TB cases in 2014. These states were noted to have higher 
numbers of foreign born persons ranging from 16-26 % of the total population.   In a broader 
view, the Hispanics remained largely affected while a decline in rates was observed in other 
groups particularly the whites [5].   
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Figure 1. Number and rate of newly diagnosed TB cases among US and foreign born persons by 
year, 2002-2014; Source: National TB Surveillance System: Morbidity and Mortality Weekly Report 
(MMWR) Tuberculosis Trends  
 
2.2. Drug Resistant TB epidemiology 
 
For the period of 2010-2013, there were a reported 9% TB cases that were, at least, resistant to one 
of the four major TB drugs. TB cases had declined nationally by 2014 but the proportion of drug 
resistant TB cases have remained high especially Isoniazid which increased from 7.9 % in 2000 to 
an estimated 9 % in 2013. Drug resistant TB was mostly observed in persons of foreign origin 
compared to US born persons. As a result, by 2013, about 90% of MDR-TB cases were recorded 
in persons born outside the USA. Anti-TB drug resistance is a growing health problem in the 
United States and globally and it is a major threat to TB control initiatives. Drug resistant TB is 
very rare in the United States as compared to Asia and Sub-Saharan Africa [5].   
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2.3 Aging and TB/DM 
Aging is a complicating factor for chronic diseases in most population and warrants further 
investigation in TB/DM comorbidity. Type 1 and type 2 diabetes are pathologies along the same 
spectrum of disease and complications. Type 2 DM risk increases with age and poses a much 
larger threat at population level since TB patients with DM are largely older than TB patients 
without Diabetes, the double jeopardy of aging and the setting of type 2 diabetes complicates an 
already complex problem [4].  
 
Conclusive pathophysiological cascade is not clear how DM is a risk factor for TB. Suggestively 
it is attributable to compromised cellular immunity and deficiency in alveolar macrophages 
response to tubercle bacilli [25]. In an effort to understand host susceptibility to TB, Qu et al, 
conducted a longitudinal diabetes study in a Hispanic cohort to analyze their gene expression of 
TB gene candidates to explore the molecular cascades in the associated TB risk in diabetics [34]. 
This was the Hispanic population that another study found that persons with diabetes aged 35- 
years to 64 years accounted for about 50% of the TB cases [35]. Qu et al over a period of three 
years profiled sampled genes of RNA. The study showed reduced expression and genes that play 
an important role in macrophage function particularly Gene H2K which mediates aerobic 
glycolysis known to be a source of energy for macrophages [34]. This could in part explain the 
reduced function of macrophages in Diabetics predisposing patients to TB.   
A study in India highlighted the intensity of TB/DM comorbidity [36]. In a similar study Baker 
et al conducted a systemic review of 33 studies and discovered that DM does not only increase 
the risk of TB but also its severity [12]. In a prospective cohort study in Mexico of TB, an OR of 
1.51 was observed for delayed sputum conversion and an OR of 2.93 for treatment failure in 
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diabetics [32] indicating that DM increases the risk of treatment failure amongst people on anti 
TB treatment. Christie Y Jeon and Megan B Murray conducted a systematic review of 13 studies 
that studied TB and DM comorbidity mainly to provide a summary of existing evidence showing 
association and to further assess the quality of the studies conducted paying particular attention 
to the methodologies implemented [17]. Their review and conclusion didn’t fall far from existing 
studies and findings. Their meta-analysis is corroborated in Demlow et al. study of 2015 which 
found that diabetes was much more common in people with TB [21]. 
The researchers conducted a retrospective study of TB cases in California for the years 2010-2012 
and observed that the overall risk of TB among diabetics was 3.5 [21]. Christie Y Jeon and Megan 
B Murray further concluded that DM was responsible for 67% of pulmonary TB cases among 
people with DM. This was based on the Mexico border study assuming a Relative Risk of 3 and 
6% prevalence in Mexico [17]. Another interesting study found that the death rate is 6 times 
higher among TB DM co-infected patients receiving anti-TB treatment. Many critical questions 
remain unanswered indicating a need for further research [37]. Epidemiologic models in India 
indicated that diabetes accounts for 14.8 % of pulmonary TB. DM prevalence in urban places is 
associated with 15.2% incidence in smear positive Pulmonary TB as compared with rural 
population [36]. In Tanzania, 1990, a study found that DM is four times more common in patients 
with TB. Inconsistent findings reveal that the connection between DM and TB is much higher 
than HIV/AIDS and TB, which is by far a well-known and established comorbidity. In a 
retrospective study in Mexico, DM/TB comorbidity exceeded HIV/TB comorbidity. A similar 
study in Brazil showed consistency with the Mexico study revealing a DM/TB comorbidity of 16 
% of death compared to 11% death in TB/HIV comorbidity [35]. 
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3. CHAPTER THREE: METHODOLOGY 
3.1. Research design 
The study employed a retrospective cross-sectional descriptive case based study design involving 
patients diagnosed with pulmonary Tuberculosis between 2009 -2014. Diabetes mellitus and 
drug-resistant TB and other known risk factors were analyzed. The purpose was to determine the 
association, if any, of DM and Drug-resistant TB in the state of Florida comparing population 
below 40 years and above 40 years. This objective included identifying the risk of association 
between drug resistant TB and DM among TB patients to determine any causal relationship as 
cited by other studies. The study further explored county TB/DM comorbidity to identify 
counties at highest risk of TB and finally established if levels of urbanization using population 
density as a proxy had a correlation with the prevalence rate of TB/DM in the different counties. 
Therefore, a population-based cross-sectional retrospective study of patients with TB diagnosis 
in Florida was employed. Patients with TB are recorded in the Florida TB registry which was the 
principal source of data. DM as a risk was not recorded as a risk factor for TB until 2009. This 
study reviewed retrospective data collected in the Florida state TB registry.  
 
Data collected between 2009 and 2014 were selected to allow for the inclusion of the DM variable. 
However, the data did not categorize DM by type and all cased were recorded as DM without 
stating the type. The registry is formed by data collected by health professionals in the TB control 
program from medical records. 
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3.2    Study population 
The study population was all adult TB patients in the registry. However, the sample population 
was all pulmonary TB patients reported between January 2009 and December 2014. Florida has 
low TB rates, just like the rest of the US when compared with Africa and Asia and a comparative 
risk between young population and old was considered important for TB control in the state. 
Ideally, patients with TB under 40 years would have been excluded from the study, but for the 
purpose of comparison they were not excluded and all individuals fulfilling the required criteria 
were all included. The registry was queried for known risk factors for TB and diabetes, the 
patient’s age, ethnicity, country of origin and gender amongst other variables. 
 
3.3. Inclusion criteria:  
 People diagnosed with Pulmonary TB regardless of age 
 People diagnosed with either type 2 DM or Type 1 DM 
 Florida residents 
3.4. Exclusion criteria:  
 Meeting all the above criteria but not a Florida resident. Each study participant was 
screened for study eligibility prior to enrollment 
 
3.5. Study setting  
Florida is the 26th largest state in the US measuring 53997sq miles and an estimated population 
of 20271272 according to The United States Census Bureau. There are 67 counties consisting of 
highly urbanized and farmlands. Some counties are large farm lands, but the majority is 
urbanized. As of 2013, 19.4 % of the population were foreign-born which is higher than the 
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national average of 12.9 %. Foreign-born population held the highest risk of TB in the state at 62% 
according to Health management systems 2014.  
 
3.6. Data collection 
Data access was granted by the Florida department of health. The data were de-identified for 
ethical concerns and zip code analysis was not feasible which posed as a limitation. The dataset 
was received in Microsoft excel format and exported to SAS for analysis. The dependent variable 
was drug resistant Pulmonary TB and all enrolled subjects had TB. The key independent variable 
was Diabetes Mellitus, which was captured by TB risk factors in the registry.  In addition to the 
key variable of DM, the research collected and analyzed data on the following variables; Age, 
Sex, gender, born or not born in the USA, country of origin, ethnicity, Race and other socio-
economic factors including homelessness and occupation. The date of TB diagnosis was captured, 
but DM diagnosis was not captured by the registry. This was a major limitation for establishing 
causality because the date of diagnosis or onset of DM would have strengthened the causal 
relationship in this study. In most literature, however, DM is usually diagnosed before TB, which 
forms the assumption that DM is the risk factor for TB. 
Population with diabetes was based on Florida charts estimates for the corresponding years of 
2009-2014. Florida charts is a state managed information system that is periodically updated to 
provide information on disease trends and statistics. Both adults aged above 40 years and those 
below 40 years formed the TB and DM estimates at the population level. These statistics were 
crucial in odds ratios for known risk factors. 
Data quality checks were performed to ensure each field was accurately and completely recorded. 
Aggregated data were verified for plausibility and interpretability. Trial runs for analysis were 
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implemented to observe for data anomalies such as missing variables. Statistically, outliers that 
could indicate heteroscedasticity were modified for good model fit. Data cleaning mainly 
manually was done to remove duplicates and account for missing values.  Data access was limited 
to persons directly involved in the study to maintain confidentiality. There was no sensitive 
information in the data sets but further confidentiality measures were ensured to ensure that the 
data was not shared beyond the limits the research. 
 
3.7. Data analysis 
Data were received in excel spreadsheets and exported to SAS 9.4 for analysis. 95 % confidence 
intervals were obtained using SAS. The acceptable level of error was 00.5 and P-values of <0.05 
were significant when at two-tailed T-Test was applied for the continuous variables. Since two 
significant groups were analyzed, the TB/DM group and TB without DM only group, a chi-
square test was performed for the categorical variables. The prevalence of TB in Florida, just like 
most of the states is not alarmingly high, and the analysis of the odds ratios was not different 
from risk ratios, but we chose to report the odds ratio in this study since it talks directly to the 
study objectives. Data were summarized using descriptive statistics.  For country of birth, the 
data were categorized into two places of origin; US born and those born outside the US and 
Canada were classified as foreign born. Since diabetes is not a notifiable disease, the state of 
Florida does not have a diabetes surveillance registry and in that regard, we were not able to 
make a causal relationship analysis but simply explored the characteristics of TB patients with 
DM. To account for this discrepancy, the data were stratified into age categories with 5-year 
intervals; (40-45, 46-50, 51-55, 56-60, 61-65, 66-70 and 71 years and above). Using TB prevalent 
cases, annual TB incidence was calculated for the patients with and without diabetes to estimate 
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the rate per 100 000 population. Prevalent cases from the Florida charts formed the denominator 
for analysis and the numerator was obtained from the recorded cases of TB and DM from the 
Florida TB registry. Continuous variables were expressed as mean or median with standard 
deviation and proportions used for categorical variables. 
 
3.8. GIS and geo-spatial analysis 
Researchers have employed GIS in several TB studies to geospatially examine trends and clusters 
of the disease. In this study, we overlay descriptive epidemiological analysis of two epidemics, 
TB and DM to provide a spatial summary of their divergence and occurrence throughout the state 
of Florida.  
 
This study determined spatial patterns of TB/DM comorbidity through the application of 
negative binomial regression for more precision and establishment of high disease prevalent 
counties, normally presented as hot spot analysis. For geographic analysis of the two disease 
patterns, prevalence maps were created through Esri’s Arc Map 10.3. Population density figures 
were used as a proxy for urbanization. This was aimed at analyzing the level of urbanization 
which is known to have a positive correlation with both diseases. Choropleth maps downloaded 
from open source diva-GIS to designate boundaries. 
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3.9. Ethical considerations 
The principal concern of this research was privacy and confidentiality of patient’s data, but there 
were no identifiers since the lowest landmark was county level not patient level outcome. The 
study relied entirely on secondary data, hence, no social or psychological harm were experienced 
by study subjects. Specifically, all data obtained from the state health department were de-
identified before release and the department granted permission to use the information because 
of the potential to inform TB program planning. Names, addresses, phone numbers, social 
security numbers and any other information that renders one capable of identifying specific 
individuals were not included. 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
 
 
4. CHAPTER FOUR: RESULTS 
4.1.  Characteristics of TB patients enrolled in the study 
 
The study reviewed de-identified data of 3836 Pulmonary TB patients. The results are presented 
as a comparison of patients with DM and those without DM. The eligibility of patient records 
reviewed fulfilled the inclusion criteria of the site of TB infection being pulmonary diagnosed 
either through case definition by a clinician or laboratory confirmed. Laboratory confirmed cases 
of TB were 82% and 18 % were diagnosed by the provider through case definition. The majority 
of the cases were males (64.6%) and 35.4% were females. Homeless persons in the year preceding 
diagnosis accounted for 9.4% of the TB cases. Equal proportions were observed for country of 
birth, broadly classified as USA born or Foreign born, 51.5 % and 48.5 % respectively amongst 
>40 patients with DM. The proportion of TB cases reported per year did not vary much with a 
mean of 639 cases reported a year. The highest disease frequencies were recorded in 2009 and 
2010: 19 % and 18 %respectively (see Figure 1). A slight decline of cases was noted in 2014 
compared to previous years (See figure 2). Most of the TB patients were non-Hispanic/Latino (72 
%). Approximately 50% were racially white and 37 % were black. Miami-Dade was the state with 
the highest proportion. Unemployed patients were 59.1 %, employed 24.84% and retired were 
2.29%. There were 72.76 % patients that were HIV negative and 12.25% of the cases were HIV 
positive. Homeless patients accounted for 9.38% of the study population. Alcohol intake in the 
year preceding diagnosis was reported by 19.9% of the population.  
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Table 1: Demographic characteristics of pulmonary TB by DM status in the state of Florida, 
USA, 2009 -2014 
Characteristics   Patients with DM                 Patients without DM     
   (n)  (%)   (n)  (%)                    
All   469  12.23   3367  87.77 
Gender 
 Male  320  8.34   2157  56.23 
 Female  149  3.88   1210  31.54 
Age Group 
<=40 years  52  1.36   1295  33.71 
>40 years  
40-45   47  1.23   376  9.80  
46-50   52  1.36   373  9.72   
51-55   59  1.54   363  9.46 
56-60   60  1.56   280  7.30 
61-65   47  1.23   209  5.45 
66-70   39  1.02   146  3.81 
70 and above  113  2.95   327  8.52 
Race and Ethnicity 
Hispanic  136  3.55   930  24.24 
Non-Hispanic  2437  63.53   333  8.68 
Black   174  4.54   1256  32.74 
White   231  6.02   1725  44.97 
Asian   59  1.54    366  9.54 
Other     5  0.65   20  0.52 
County of birth 
USA   203  5.29   953  24.84 
Foreign Born  266  6.93   1711  44.60 
Employment 
Employed                99  2.59   953  24.84 
Unemployed               328  8.55   2267  59.1 
Retired                 46  1.04   88  2.29 
Alcohol Consumption 
Alcohol Past year            66  1.72   664  17.36 
No alcohol past year 403  10.51   2680  69.86 
HIV  
Positive  35  0.91   435  11.34 
Negative  352  9.18   2439  63.58 
Unknown  82  2.14   493  12.85 
TB Diagnosis 
Laboratory confirmed 420  10.95   2733  71.25 
Case definition   49  1.28   634  16.53 
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Figure 2. Proportion of TB cases per year, 2009-2014 
Figure 2 above indicates Proportions of PTB cases, 2009-2014. The years 2009 and 2010 recorded 
the highest proportions, 20.65% and 18.22 % respectively. A gradual decline in the trends was 
observed from 2009 until 2014 with 2014 recording 14.23 % of the Total TB cases.   
 
 
4.2. TB patients with Diabetes Mellitus 
 
The study further profiled TB cases according to DM status. The prevalence of DM in this 
population of TB patients was 12% (469/3836), in the < 40 years it was 3.9% (52/1345) while in 
those older than 40 years it was 16.5 % (417/2513). TB patients with DM infection were more 
likely to be old, above 40 years, Mantel-Haenszel Crude Odds Ratio of 4.99; 95% Confidence 
interval [3.7-6.7] (P <.0001). Using the white race as a reference group, black people had an OR 
1.4 to be TB patients with DM [CI 1.132-1.835; P-value 0.003. Foreign born patients had an OR 
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5.09; [CI 3.4-7.6] P-Value 0.02. There was an observed pattern where OR increased with age 
among TB patients to have DM. Age category 70 years and above had an OR 8.59 with CI [5.93-
12.44] p-value <.0001. 
 
Table 2. Age adjusted Odds Ratios for TB cases with DM by age category, Florida, USA, 2009-
2014 
Age Category        Odds Ratio          95% CI             Pr > ChiSq  
40-45   3.64   2.40 5.53   <.0001 
46-50   4.51   2.98 6.81   <.0001 
51-55   5.09   3.40 7.62   <.0001 
56-60   6.36   4.25 9.50   <.0001 
61-65   6.50   4.22 10.02   <.0001 
66-70   6.85   4.33 10.8   <.0001 
70 and above  8.59   5.93 12.44   <.0001 
 
 
 
    Table 3. Analysis of DM associated risks among TB patients 
Characteristics  Odds Ratio      95% CI                           Pr > ChiSq 
Alcohol              0.589   0.437 0.795   0.0005 
Race/Black  1.441   1.132 1.835   0.0030 
Ethnicity  5.09   3.40 7.62   0.0195 
HIV Positive  0.501   0.340 0.739   0.0005 
Hispanic  1.236   0.936 1.631   0.1351 
Gender/Sex  1.150   0.921 1.435   0.2168 
Unemployed  0.805   0.624 1.040    0.0970 
 
An analysis of association was conducted for drug resistant TB and DM among patients 
diagnosed with TB. From the total of 3686 pulmonary TB cases, 275 (7.4%) patients had drug 
resistant TB and the majority (87.3%) were resistant to Isoniazid. Unadjusted Drug resistance OR 
was 1.4; CI [1.002-1.971]. Patients with Diabetes had an adjusted OR 1.5, CI [0.52 – 4.4] which 
indicate an association that was not significant. Alcohol consumption, African American and 
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native people born in the United States indicated a positive association between DM and drug 
resistant TB among patients with TB using age as an effect modifier (see table 4 below).  
 
Table 4. Analysis of DR-TB risk among Diabetics 
Characteristics  N Resistant (n)  OR      95% CI  Pr > ChiSq
   
DM   469  44  1.41   1.002    1.97  0.047 
 
 
The odds ratio of DR-TB amongst diabetics was 1.41, 95% CI [1.002, 1.97] p-value 0.047. The odds 
ratio seems to be low but significant showing an association of drug resistant TB and DM. 
 
Table 5. Crude Odds Ratio for Drug Resistant TB associated risks 
 
 
 
 
Characteristics    
ODDS 
RATIO
 95%        
       Confidence 
Limits       
 Pr > ChiSq 
DM 1.34 0.99 1.97 <.0001 
Alcohol 1.45 1.05 2.00 0.056 
Black Race 0.73 0.53 0.99 0.042 
Foreign Born 0.45 0.33 0.61 <0.001 
HIV positive 1.37 0.93 2.01 0.11 
HIV unknown 0.75 0.50 1.12 0.16 
Hispanic 0.67 0.49 0.93 0.02 
Un-employment 0.88 0.66 1.16 0.36 
Male gender 1.2 0.92 1.60 1.17 
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Table 6. Adjusted Odds Ratio by age >40 years for Drug Resistant TB associated risks 
 
Characteristics  ODDS RATIO           95% Confidence Limits          Pr > ChiSq 
DM 1.502                 0.517 4.362 0.4545 
Alcohol Consumption 2.192                 1.158 4.149 0.0159 
Black Race 0.522                 0.296 0.922 0.025 
Born in the USA 0.434                 0.249 0.756 0.0032 
HIV positive 1.16                 0.524 2.566 0.714 
HIV unknown 0.662                 0.295 1.486 0.317 
Hispanic 0.604                 0.354 1.03 0.0639 
employment 0.878                 0.544 1.418 0.5945 
Sex 0.915                 0.577 1.45 0.7044 
 
 
There was no observed association between the development of drug resistant TB amongst TB 
patients with Diabetes when adjusted for age > 40 years and the results were insignificant in this 
analysis. 
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4.3. TB and Diabetes prevalence rates by County  
 
 
 
Figure 3. TB prevalence rates by county, Florida, USA, 2012 
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Figure 4. Diabetes Mellitus prevalence rates by county, Florida, USA, 2012 
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Table 7. Analysis of population density as a risk factor for increased TB/DM comorbidity 
 
Analysis Of Maximum Likelihood Parameter Estimates 
Parameter DF Estimate 
Standard 
Error 
Wald 95% 
Confidence Limits 
Wald Chi-
Square 
Pr > 
ChiSq 
Intercept 1 -10.5418 0.2367 -11.0057 -10.0779 1983.94 <.0001 
Pop_Density 1 -0.0008 0.0002 -0.0012 -0.0004 15.46 <.0001 
Total TB Cases 1 0.0079 0.0015 0.0048 0.0109 26.21 <.0001 
Dispersion 1 1.4380 0.3547 0.8867 2.3321   
 
 
Population density, a proxy used for urbanization did not seem to influence the distribution of 
TB positively. A negative binomial regression analysis indicated a significant protective effect (P-
Value 0.008) whereby for each one unit increase in Population Density the expected log count of 
TB/DM comorbidity cases decreased by 0.001.and this is probably attributed to the omission of 
other risk factors in the model. Further studies would need to be done to test this association since 
it can provide pivotal information for TB control programs. The model was tested and it was a 
good fit with R-Square 0.9. 
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5. CHAPTER FIVE 
5.1. Discussion 
Diabetes Mellitus is associated with TB. This is a known phenomenon that has been established 
and recorded in numerous literature. In this retrospective cross-sectional population based study 
of TB cases in Florida, USA, the characteristics of TB patients with DM and drug resistant TB were 
explored. Age was used as an effect modifier when evaluating the association between DM and 
Drug resistant TB amongst patients with Pulmonary TB. The association between DM and TB 
was not feasible to establish because of secondary data limitations which was a huge 
methodology issue but nonetheless, the study was able to explore known TB risk factors amongst 
diabetics to evaluate the characteristics of patients co-infected with TB and DM. The results did 
not show causality pattern or risk of developing TB amongst diabetics but the evaluation of the 
characteristics and known risks are empirical to draw hypotheses that will influence further 
research in the field.  
This study analyzed the prevalence of DM amongst the TB patients and it observed that the 
prevalence increased with age. The overall prevalence was 12% but when categorized by age, in 
the < 40 years category, the prevalence of DM was 3.9% compared to 16.7% amongst those aged 
above 40 years. The results are not significantly different from a study that was conducted in 
India that recorded a diabetes prevalence of 15.3 % among TB patients in India.  These findings 
show the influence age has on TB/DM comorbidity. The majority of TB patients with DM in this 
study were older, > 40 years in keeping with findings from studies exploring the convergence of 
the two epidemics, [17]. Logistic regression analysis comparing the odds ratios for the <40 years 
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and > 40 years group indicated that the ratio was high amongst the older category, reaching 8.6 
amongst those aged 70 and above with a CI [6.0 – 12.2]. The odds ratio increased every 5 units of 
age category symbolizing a dose-response pattern by age. Since this study did not warrant 
causality, it is prudent to investigate further the role of aging in DM attributable risk to TB 
especially Type 2 diabetes in the aged population. Such research will be important in Florida 
particularly since the mean age of the population is 41 years signifying that most people are older 
and prone to diabetes and subsequently TB. Findings from such a study would reveal the risk 
and number of people needed to treat to prevent further TB infections as well as providing 
information as to whether it would be beneficial to start preventive therapy in the aged 
population.  Analyzing TB treatment outcomes in the older age group would have provided 
further pertinent information for program use. 
 
This study further examined the association between drug resistant TB and DM amongst the 
patients. Studies have shown that TB and DM confluence each other and the relationship could 
be reciprocal. TB can inversely impact DM control by inducing glucose intolerance and poor 
glycemic control among diabetics thus complicating DM control further. Likewise, DM interferes 
with TB treatment, particularly rifampin. The study concluded that increasing age, black race and 
non-US born persons are at an increased TB/DM comorbidity. These study findings are not 
different from Viswanathan et al study in India that found out that age, diabetes history and non-
active occupation were the most identified risk factors for DM among patients with TB. Alcohol 
consumption was found to have a higher association with diabetic in patients with TB and these 
results corroborate study findings by Raghuraman et al which found similar output following 
33 
 
logistic regression analysis of DM risks in TB patients [38].  With DM on the increase in the United 
States and globally, this study magnifies the emerging threat to TB control initiatives.  
High DM prevalence was observed in TB patients however attributable risk ratios would have 
provided better information on causal effects of DM on TB but this analysis was not possible in 
this study. As a result, it would be plausible to conduct a population based retrospective cohort 
study enrolling newly diagnosed DM patients and follow them over years to determine the risk 
of developing TB.  
 
Faurholt-Jepsen et al in their earlier studies reported that DM has no clinical significance in the 
presentation of TB [31]. However, a similar study was carried out by the same researchers in 
Tanzania and they documented that DM negatively affects TB treatment outcomes [31]. Several 
studies have provided evidence that TP patients have much more severe TB when they have DM 
since DM is associated with reduced cure rate and resistance to treatment [39]. Evidence further 
shows that DM complicates absorption of anti-TB drugs which could explain in part why, though 
not significant, our study found that diabetes is associated with drug resistant TB. This could 
have resulted in part due to the small numbers of drug resistant TB. It is convincing to 
hypothesize that different populations would yield different results while applying the same 
research methodology. Unlike the USA, where the rates of TB are low and DM control is well 
coordinated, other parts of the world with limited resources like Africa and Asia have high 
disease prevalence for both DM and TB, and the control program for these diseases are not well 
coordinated, resulting in poor disease control and treatment outcomes. This would partly account 
for the positive association presented by Restrepo et al in Tanzania, 2007, [15]. 
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Seven point two percent (7.2%) of the TB cases were drug resistant to mainly rifampin which 
literature has cited as a DM metabolism effect on rifampin absorption, therefore, resulting in 
reduced drug availability leading to the development of resistance over time. Significantly true, 
this study did not evaluate the effect of DM on treatment outcomes among TB patients or 
mortality thereof but we can learn from other studies [11] that DM has detrimental effects on 
treatment success and mortality. Faurholt-Jepsen et al in their study observed that out of 6 
patients with TB, one had DM and about 50 % of reported death occurred in the first 60 days of 
initiating treatment amongst diabetics due to treatment failure [31].  
 
In this analysis, population density, a proxy used for urbanization did not seem to influence the 
distribution of TB. A negative binomial regression analysis indicated a protective effect with and 
this is probably attributed to the omission of other risk factors in the model. Further studies would 
need to be done to test this association since it can provide pivotal information for TB control 
programs. 
 
5.2. Limitations 
1.    The study implemented a retrospective cross-sectional study design and as a result, the 
causality or sequence of events could not be established. All persons had the dependent variable, 
but the study could not establish which was diagnosed first between TB and DM, hence, causality 
could not be inferred. 
2.    Data sources and unavailability of DM data from available sources was a major limitation. 
The State of Florida does not routinely report on DM. To establish causal relationship TB cases 
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and Data cases needed to be merged according to unique identifiers and followed over time to 
establish the rates at which cases developed the disease. A prospective cohort study would have 
been more ideal for this research. 
3.    It would have been more informative to have patient-level data to determine clusters based 
on transmission or the occurrence of TB. Patient-level cluster analysis would have provided the 
precise location beyond county or zip code analysis, but the lack of such identifiers in the data set 
received limited this analysis. 
 
5.3. Conclusion 
Diabetes Mellitus, aging, low immunity and several other medical conditions are linked with the 
risk of progressing from latent TB infection to active disease. To achieve the national goal of TB 
elimination, it is important to fully understand and identify known comorbidities among patients 
with TB to facilitate proper diagnosis and early initiation into care. In numerous circumstances, 
the high prevalence of diabetes in TB populations have been demonstrated and this study shared 
the same findings. The rates of TB and Drug resistant TB in the US are not alarmingly high as the 
rest of the world but the increase in DM poses a greater threat in the future. It is therefore 
recommended that prevention of DM, management of hyperglycemia and comprehensive care 
of diabetes is made a priority for stakeholders involved in the prevention of both communicable 
and non-communicable diseases.   
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APPENDIX 1: Communication with the Florida Department of Health 
 
Per our discussion yesterday I’m sending you the TB data from 2000-2014.  (Please note the data 
is derived from two different sources and contained on two worksheets.)  If known, the HIV 
status is documented for each case.  However, additional risk factors, such as diabetes, weren’t 
collected for TB cases until 01/01/2009.   Please note the following: 
 
1. We have provided you with a de-identified data set without zip codes. 
2. We do ask if any publication is to be done that we are notified as a courtesy. 
 
Please let me know if you have questions about the data. 
 
Lori Johnston 
TB Surveillance Manager 
Bureau of Communicable Diseases, TB Control Section 
Florida Department of Health 
8515 N. Mitchell Ave, Tampa, FL  33604 
Phone: (813) 307-8015 ext. 4771 
Cell: (813) 299-1295 
Fax: (850) 921-9906 
 
DOH Mission: To protect, promote and improve the health of all people in Florida through 
integrated state, county and community efforts. 
 
**Please Note: Florida has a very broad public records law.  Most written communications to or from 
state officials regarding state business are public reocrds available to the public and media upon 
request.  Your email communications may therefore be subject to public disclosure. 
 
From: Mkhontfo, Mandzisi [mailto:mandzisim@health.usf.edu]  
Sent: Thursday, September 24, 2015 3:36 PM 
To: Johnston, Lori A. <Lori.Johnston@flhealth.gov> 
Cc: Novak, Robert <rnovak@health.usf.edu> 
Subject: TB, HIV and Diabetes data for Florida 
 
Dear Lori Johnson 
 
My name is Mandzisi Mkhontfo. I am a Master of Public Health Student at the University of 
South Florida. I am working with Dr. Robert Novak and Dr. Benjamin Jacobs on a Tuberculosis 
research. The purpose of the research is to compare the odds of developing pulmonary 
tuberculosis amongst people with Diabetes and those with HIV, with the hypothesis that the 
risk of disease is much higher amongst aged population with diabetes as compared to HIV. The 
study will be based on the state of Florida. 
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Part of the objective is to evaluate the risk of disease based on population distribution and 
spatial analysis. This is aimed at developing a predictive model to predict which areas will 
require urgent public health intervention to prevent the spread of TB. 
 
In that regard, I am requesting your department to provide me with Tuberculosis, Diabetes and 
HIV data for the past 15 years, preferably from year 2000 to 2014. I am interested in all the 
variables you collect for each of the disease, when the cases were diagnosed for TB, HIV and 
Diabetes. The data will help me test the hypothesis and evaluate it against known risk factors. 
 
I am willing to engage in a telephonic discussion with you in case you need more clarity. 
 
Thank you 
 
 
 
Mandzisi Mkhontfo, MSPH Candidate 
Global Communicable Diseases 
College of Public Health 
Department of Global Health 
University of South Florida 
Mobile 813.420.8864 
mandzisim@health.usf.edu 
 
 
 
 
 
 
 
 
 
 
 
